Condition category
Eye Diseases
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status

Plain English Summary

Background and study aims
There are approximately 600,000 individuals in the UK with Age-related Macular Degeneration (AMD), which is a painless condition which causes loss the to an individuals’ central vision, causing the vision to become increasingly blurry. AMD exists in two forms ‘wet’ (neovascular) or ‘dry’ (atrophic), with new treatments becoming available for the ‘wet’ form of AMD, however, no treatment exists for the ‘dry’ form of AMD or those who do not respond to existing treatments. A novel treatment in AMD patients has been the use of intraocular telescopes, a magnifying lens which is implanted into the eye; this can be done at the time of cataract surgery or as a separate surgery. These intraocular telescopes provide high magnification for distance viewing while still allowing near vision tasks, such as reading, to be carried out as normal through reading glasses (if required). This study will use a novel intraocular telescope called OriLens, which uses mirrors resulting in an implant which is smaller than other intraocular telescopes currently available. The smaller size of the OriLens offers the potential for an easier surgery and a faster recovery time. The aim of this study is to evaluate the efficacy and safety of the OriLens to improve vision for those with severe AMD.

Who can participate?
Adults aged 55 to 100 who have AMD requiring treatment.

What does the study involve?
Potential participants are screened in order to make sure they are suitable for the study. They then have laster treatment in the selected eye (if they have already had this done prior this procedure is not repeated). Participants are then allocated to one of two groups. Those in the first group receive the surgery where the telescope lens is inserted. They are also tested for new glasses are provided with appropriate spectacles and low vision aids. They also receive three sessions of Low Vision Training. Those in the second group receive the three sessions of low vision training and are tested for new glasses, receiving appropriate glasses and low vision aids. All participants are asked to attend four follow up appointments where they undergo eye tests and training. They are also asked about their health and vision related quality of life. Those in the first group receive two additional appointments following their surgery.

What are the possible benefits and risks of participating?
While there is no guarantee that participants will benefit from taking part in the study, the potential benefits to participants include additional low vision training. Half of the participants taking part in the study will receive the intraocular telescope, and may benefit from magnified central vision as a result. Those receiving the intraocular telescope will require surgery to insert this, which may involve some risk. As with any surgery the main risk is infection, and in order to reduce the risk of infection antibiotics will be placed in the eye at the time of surgery and participants will be required to use eye drops for a month after the surgery. Some mild discomfort and redness in the eye is to be expected following the surgery, with eye usually being comfortable within 48 hours of the procedure, and it is expected that the eye will have healed within one month.

Where is the study run from?
This study takes at the Belfast Health and Social Care Trust (Lead Centre) and nine other sites in the UK.

When is the study starting and how long is it expected to run for?
September 2015 to February 2019

Who is funding the study?
National Institute for Health Research (UK)

Who is the main contact?
1. Dr Catherine Adams

Trial website

Contact information



Primary contact

Dr Catherine Adams


Contact details

Northern Ireland Clinical Trials Unit
1st Floor Elliott Dynes Building
The Royal Hospitals
Grosvenor Road
BT12 6BA
United Kingdom
+44 28 90635794

Additional identifiers

EudraCT number

2016-000887-40 number

Protocol/serial number


Study information

Scientific title

Efficacy of the Telescopic Mirror Implant for Age-related Macular Degeneration: The MIRROR Trial



Study hypothesis

The aim of this study is to evaluate the efficacy and safety of a new intraocular implantable device (OriLens) to improve vision in participants with severe Age-related Macular Degeneration.

Ethics approval

East Midlands- Nottingham 1 Research Ethics Committee, 23/05/2016, ref: 16/EM/0212

Study design

Randomised; Interventional; Design type: Treatment, Device

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

See additional files


Specialty: Ophthalmology, Primary sub-specialty: Retina (including Diabetes); UKCRC code/ Disease: Eye/ Disorders of choroid and retina


The study is conducted for those who have Age-related Macular Degeneration (AMD) and have had cataract surgery in both eyes. Before entering the study potential participants aree screened at two appointments to make sure they meet the needs of the study. Once a participant has been selected they have laser treatment in the selected eye (if a participant has already had the laser treatment they will not have to have the procedure repeated). The planned interventions are posterior Nd:YAG capsulotomy in the study eye (if not already done) for all eligible participants. Participants are randomised (stratified by site) after Nd:YAG capsulotomy (if required) to one of two groups:

Group 1: Surgical implantation of the OriLens device plus three sessions of low vision training

Group 2: Three sessions of optimised low vision training with the opportunity to try external telescopes for day-to-day tasks. In order to minimise the possibility of a placebo effect, an equal number of low vision sessions are given in each Group. Participants are required to attend four appointments over the course of a year, in order to monitor any changes to their vision during this period.

Appointments are arranged one month, three months, six months and 12 months following randomisation for both groups. Individuals randomised to the intervention group (Group 1) attend two additional post-operative appointments, one day and one week following surgery. Medical history, ophthalmic examination, visual acuity tests and inquiries into adverse events are conducted at each appointment. Visual rehabilitation training take place for all participants are months one, three and 12. Questionnaires to assess health service use and health and vision related quality of life are administered at months six and 12. On the final appointment (month 12) fundus photography and specular microscopy are also be performed.

Intervention type



Drug names

Primary outcome measure

BCDVA is measured using number of letters improvement on ETDRS Chart at baseline and 12 months.

Secondary outcome measures

1. BCDVA is measured using number of letters improvement on ETDRS Chart at one, three and six months
2. BCNVA, reading speed and contrast sensitivity is measured by MNRead Chart and MARS Chart at baseline and 12 months
3. Vision-specific quality of life measured using the IVI at baseline, six and 12 months
4. Health related quality of life status is measured using the EQ-5D-5L questionnaire at baseline, six and 12 months
5. Health service use and associated costs are measured by a Health Service Use Questionnaire at six and 12 months

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)

Lack of staff/facilities/resources


Participant inclusion criteria

1. Aged between 55 and 100 years (both male and female)
2. Bilateral stable advanced AMD either neovascular (required to be stable for at least 12 months after last treatment) or atrophic AMD
3. Bilateral uncomplicated cataract surgery with unifocal intraocular lens positioned within the capsular bag
4. Bilateral best-corrected distance visual acuity of 6/38-6/240 (LogMAR 0.80 to 1.60)
5. Must demonstrate a 10-letter improvement in BCDVA (ETDRS chart) with the external x2.5 telescope in the eye for implantation
6. Must have had experience of using low vision aids
7. Must have an anterior chamber depth (ACD) of ≥3mm in both eyes
8. Must have a pupil size ≥3mm in diameter in both eyes
9. Must have an endothelial cell density within normal limits for age (see appendix 1)
10. Must be willing to undergo laser capsulotomy in the eligible eye prior to randomisation (if not already done)
11. Must be three months or more following any intraocular surgical procedure and one month following YAG capsulotomy
12. Must be in good general health with every likelihood of involvement in the trial for the duration of the study and be able to physically or verbally complete the questionnaires

Participant type


Age group




Target number of participants

Planned Sample Size: 132; UK Sample Size: 132

Participant exclusion criteria

1. Cataract surgery with multifocal intraocular lenses
2. A history of glaucoma or of being on anti-glaucomatous medication
3. Any other retinal condition
4. Lack of clear view of the retina
5. Abnormal or de-centred pupil
6. Endothelial cell density <1500 cells/mm2
7. History of ocular inflammatory disease
8. Zonular instability or instability of existing intraocular lens
9. BCDVA of better than 6/38 (0.80 LogMAR) or worse than 6/240 (1.60 LogMAR) in either eye
10. Participants unable to provide informed consent
11. Be in poor general health that could compromise attending follow-up assessments
12. Difficulties with balance
13. Not fluent in English

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Belfast Health and Social Care Trust (Lead Centre)
Eye & Ear Clinic The Royal Hospitals 274 Grosvenor Road
BT12 6BA
United Kingdom

Trial participating centre

St. James’s University Hospital
Eye Clinic Beckett Street
United Kingdom

Trial participating centre

Royal Liverpool University Hospital
St Paul’s Eye Unit
L7 8XP
United Kingdom

Trial participating centre

Moorfields Eye Hospital
162 City Road
United Kingdom

Trial participating centre

St. Thomas Hospital
Department of Ophthalmology Lambeth Palace Road
United Kingdom

Trial participating centre

University Hospital Aintree
Ophthalmology Department Longmoor Lane
L9 7AL
United Kingdom

Trial participating centre

James Cook University Hospital
Eye Outpatients Marton Road
United Kingdom

Trial participating centre

Southampton General Hospital
Eye Unit Tremona Road
SO16 6YD
United Kingdom

Trial participating centre

Sunderland Eye Infirmary
Research Office Queen Alexandra Road
United Kingdom

Sponsor information


Belfast Health & Social Care Trust

Sponsor details

Knockbracken Healthcare Park
Saintfield Road
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

National Institute for Health Research

Alternative name(s)


Funding Body Type

government organisation

Funding Body Subtype

National government


United Kingdom

Results and Publications

Publication and dissemination plan

It is planned that the study findings will be published in national and international peer review journals which will be led by the CI, approximately one year after the trial ends.

IPD sharing statement:
The current data sharing plans for the current study are unknown and will be made available at a later date.

Intention to publish date


Participant level data

To be made available at a later date

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

30/11/2018: Trial stopped. 25/10/2017: The ISRCTN prospective/retrospective flag compares the date of registration with the recruitment start date and does not include any grace period. The registration of this study was requested through the NIHR Portfolio and was finalised within 6 months of the recruitment starting.